Open AccessRatio Of Serum Asymmetric Dimethyl Arginine (ADMA)/ Nitric Oxide in Coronary Artery Disease patients
Author(s) -
Rajni R. Shivkar,
Subodhini A. Abhang
Publication year - 2014
Publication title -
journal of clinical and diagnostic research
Language(s) - English
Resource type - Journals
eISSN - 2249-782X
pISSN - 0973-709X
DOI - 10.7860/jcdr/2014/7849.4665
Subject(s) - asymmetric dimethylarginine , coronary artery disease , medicine , nitric oxide , endothelial dysfunction , cardiology , myocardial infarction , unstable angina , diabetes mellitus , angina , arginine , endocrinology , chemistry , biochemistry , amino acid
Coronary artery disease (CAD) is the leading cause of mortality and morbidity in the world. Current predictions estimate that by the year 2020 cardiovascular diseases, notably atherosclerosis will become the leading global cause of the total disease burden. Atherosclerosis of the Coronary artery causes myocardial infarction and angina pectoris. Endothelial Nitric oxide (NO), released by the intact and healthy endothelium plays a very important role in the maintenance of vascular tone and structure. Decreased NO level leads to endothelial dysfunction is an initial event in the atherosclerosis. Endogenous Asymmetric dimethylarginine (ADMA) is a structural analog of L-arginine, competitively inhibits the enzyme NO synthase and thus decreases the NO level.